We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03639844
Expanded Access Status : No longer available
First Posted : August 21, 2018
Last Update Posted : October 5, 2020
Information provided by (Responsible Party):
Bellicum Pharmaceuticals

Tracking Information
First Submitted Date August 17, 2018
First Posted Date August 21, 2018
Last Update Posted Date October 5, 2020
Descriptive Information
Brief Title BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 Study
Official Title Expanded Access Protocol for CaspaCIDe T Cells From An HLA-Partially Matched Related Donor After Negative Selection of TCR αβ+T Cells In Pediatric Patients Affected by Hematological and Other Disorders
Brief Summary Providing access of BPX-501 gene modified T cells and rimiducid to pediatric patients who do not meet the eligibility criteria of the BP-U-004 study.
Detailed Description

This is an expanded access protocol of BPX-501 T cells infused after T cell-depleted HSCT in pediatric patients with non-malignant hematologic disorders eligible for treatment on the BP-U-004 study.

The purpose of this protocol is to provide access to the CaspaCIDe system combination product (BPX-501 gene modified T cells and rimiducid) to patients on a case by case basis who do not meet the BP-U-004 protocol eligibility criteria. BPX-501 infusion can enhance immune reconstitution with the potential for reducing the severity and duration of severe acute GVHD.

Study Type Expanded Access
Expanded Access Type Individual Patients
  • Hurler Syndrome
  • Inherited Metabolic Disorder
  • Lysosomal Storage Disorder
  • Metachromatic Leukodystrophy
  • Inborn Errors of Metabolism
  • Biological: rivogenlecleucel
    BPX-501 T cells are genetically modified with a suicide safety switch. The cells are infused after T cell-depleted HSCT to potentially enhance immune reconstitution while reducing severity and duration of GVHD.
    Other Name: BPX-501 T cells
  • Drug: rimiducid
    Rimiducid induces activation of the Caspase 9 suicide gene in BPX-501 T cells inducing apoptosis of the modified T cells in case of GVHD
    Other Names:
    • AP1903
    • Rimiducid for Injection
    • AP1903 for Injection
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Recruitment Information
Expanded Access Status No longer available
Eligibility Criteria

Inclusion Criteria:

  1. Males or females
  2. Age < 21 years and > 3 months
  3. Life expectancy > 10 weeks
  4. Patients deemed eligible for allogeneic stem cell transplantation.
  5. Non-malignant disorders including:

    1. inherited metabolic disorders such as adrenal leukodystrophy;
    2. lysosomal storage disorders such as Hurler syndrome or metachromatic leukodystrophy
    3. other inborn errors of metabolism
  6. Lack of suitable conventional donor (HLA identical sibling or HLA phenotypically identical relative evaluated using high resolution molecular typing).
  7. A minimum genotypic identical match of 5/10 is required.
  8. The donor and recipient must be identical, as determined by high resolution typing, at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, and HLA- DRB1.
  9. Lansky/Karnofsky score > 50
  10. Signed written informed consent

3.2 Subject exclusion criteria

  1. Age < 3 months or >21 years
  2. Patients with non-malignant disorders eligible for treatment on the BP-U-004 study:

    1. primary immune deficiencies,
    2. severe aplastic anemia not responding to immune suppressive therapy,
    3. osteopetrosis,
    4. selected cases of hemoglobinopathies and
    5. congenital/hereditary cytopenia, including Fanconi Anemia before any clonal malignant evolution (MDS, AML)
  3. Greater than Grade II acute GVHD or chronic extensive GVHD due to a previous allograft at the time of inclusion
  4. Patient receiving an immunosuppressive treatment for GVHD treatment due to a previous allograft at the time of inclusion
  5. Dysfunction of liver (ALT/AST > 5 times normal value, or bilirubin > 3 times normal value), or of renal function (creatinine clearance < 30 ml / min)
  6. Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or left ventricular ejection fraction < 40%)
  7. Current active infectious disease (including positive HIV serology or viral RNA)
  8. Serious concurrent uncontrolled medical disorder
  9. Pregnant or breast feeding female patient
  10. Lack of parents'/guardian's informed consent.


Sexes Eligible for Study: All
Ages 3 Months to 21 Years   (Child, Adult)
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
Administrative Information
NCT Number NCT03639844
Other Study ID Numbers BP-C-004
Current Responsible Party Bellicum Pharmaceuticals
Original Responsible Party Same as current
Current Study Sponsor Bellicum Pharmaceuticals
Original Study Sponsor Same as current
Collaborators Not Provided
Study Director: Bellicum Pharmaceuticals Bellicum Pharmaceuticals, Inc.
PRS Account Bellicum Pharmaceuticals
Verification Date October 2020